U.S. Medical Centers Need a New Model for Drug Discovery and Development

"For more than 50 years, U.S. academic medical centers (AMCs) have been the global engine for pharmaceutical innovation, dedicated to medical education, scientific research, and patient care."

"U.S. AMCs have developed a distinctive innovation model where patient care inspires research questions, public investment supports discovery, and public-private partnerships enable translation into clinical practice."

"China has emerged as a major rival in the last decade, with its pharmaceuticals R&D sector on track to become the global industry leader, displacing its U.S. counterpart."

U.S. academic medical centers have driven pharmaceutical innovation for over 50 years, focusing on medical education, research, and patient care. Their unique model connects patient care to research, supported by public investment and public-private partnerships. However, in the last decade, China has emerged as a formidable competitor, with its pharmaceuticals R&D sector poised to surpass that of the U.S., potentially becoming the global leader in the industry.

Read at Harvard Business Review